Boehringer Ingelheim and Enara Bio join forces to discover cancer immunotherapies
15th January 2021
Boehringer Ingelheim has entered a strategic collaboration with UK biotech Enara Bio to research and discover novel targeted cancer immunotherapies.
The agreement will leverage Enara’s Dark Antigen discovery platform to identify and validate novel dark antigens in up to three tumour types across the lung and gastrointestinal cancer areas.
Dark antigens are a new class of cancer-associated antigens that derive from genomic dark matter – the portion of the human genome that is normally not expressed as protein.
In healthy cells, dark antigen-encoding sequences are usually silenced but are activated and presented on tumour cells – they are often associated with specific cancer types and are shared across patients.
(2)
Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers
Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim s position in the cancer vaccine and T-cell engager spaces
Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio s EDAPT platform and Dark Antigen discovery work and supports ongoing cell therapy based therapeutic approach
Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio s Dark Antigen discovery platform. This new collaboration combines Boehringer Ingelheim s approach to tackle cancer through pairing leading science with innovative immune-oncology platforms, such as oncolytic viruses and cancer vaccines, with Enara Bio s expertise in cancer antigen identification. The aim is to provide poten